Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)
Recruiting
N/A
Interventional Study
Overt Hepatic Encephalopathy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 174 (estimated)
- Sponsor
- General Hospital of Shenyang Military Region · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Hepatic encephalopathy (HE), a severe complication of decompensated cirrhosis, is characterized as neurocognitive dysfunction. Emerging evidence suggests the potential role of human albumin infusion for the treatment of HE, but its optimal dosage remains undefined. Therefore, the investigators planned a randomized controlled trial (RCT) to compare the efficacy of human albumin infusion at differen…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* A definite diagnosis of liver cirrhosis and overt HE
* A serum albumin level of 23-30g/L
* Age ≥18 years old
* Sign the informed consent
Exclusion Criteria:
* Contraindications to human albumin infusion
* A history of transjugular intrahepatic portosystemic shunt
* A diagnos…
Contacts